1-4 of 4
Aditya Raju
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Clinical Characteristics and Late-Line Treatment Patterns of Patients with Chronic Myeloid Leukemia Who Received 2 Prior Lines of Tyrosine Kinase Inhibitor Therapy in US Community Oncology Practices

Pareshkumar Patel, Aditya Raju, Anna Coutinho, Rodrigo Maegawa, Orsolya Lunacsek, Kathryn Deyoung, Serban Iorga, Xiting Cao
Journal: Blood
Blood (2021) 138 (Supplement 1): 5036.
https://doi.org/10.1182/blood-2021-152619
Published: 2021
Journal Articles

Real-World Treatment Patterns and Outcomes of Proteasome Inhibitor (PI: Bortezomib [V], Carfilzomib [K], or Ixazomib [I])-Lenalidomide/Dexamethasone (Rd)-Triplets By Prior Lenalidomide-Exposure in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Engaged in Routine Care in the United States (US)

Larysa Sanchez, MD, Dasha Cherepanov, Dorothy Romanus, RPh, PhD, Aditya Raju, Marlo Blazer, PharmD, Eileen Farrelly, Dawn Marie Stull, Sikander Ailawadhi
Journal: Blood
Blood (2020) 136 (Supplement 1): 47–48.
https://doi.org/10.1182/blood-2020-136597
Published: 2020
Journal Articles

Comparative Effectiveness of Triplets Containing Bortezomib (V), Carfilzomib (K), or Ixazomib (I) Combined with a Lenalidomide and Dexamethasone Backbone (Rd) in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) in Routine Care in the United States (US)

Ajai Chari, MD, Dorothy Romanus, RPh, PhD, Aditya Raju, Lauren Cain, Marlo Blazer, PharmD, Eileen Farrelly, Dawn Marie Stull, Sikander Ailawadhi, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 1827.
https://doi.org/10.1182/blood-2019-121658
Published: 2019
Journal Articles

Duration of Therapy (DOT) and Time to Next Therapy (TTNT) of Bortezomib, Carfilzomib and Ixazomib Combinations with Lenalidomide/Dexamethasone (VRd, KRd, IRd) in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Clinical Practice in the United States Vs Clinical Trial Experience

Ajai Chari, MD, Dorothy Romanus, Katarina Luptakova, MD, Aditya Raju, MS, Eileen Farrelly, MPH, Marlo Blazer, PharmD, Tomas Skacel, MD, Parameswaran Hari, MD MRCP, MS
Journal: Blood
Blood (2017) 130 (Supplement 1): 1818.
https://doi.org/10.1182/blood.V130.Suppl_1.1818.1818
Published: 2017